Drawing for BROMAC

USPTO serial 90191359

BROMAC

Reviewed by CopyMark Law Group

Reg. 6617801Status 700Renewal
Filing date
Status date
Registration date
Jan 18, 2022
Examiner
STEEL, ALYSSA PALADINO
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with BROMAC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $325

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

JOE MCKINNEY MUNCY

JOE MCKINNEY MUNCY MUNCY, GEISSLER, OLDS & LOWE, P.C.125 S. Royal StreetAlexandria, VA 22314UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-bacterial pharmaceuticals; anti-cancer drugs; anti-cancer pharmaceutical preparations; anti-fungal preparations; antiviral pharmaceutical preparations; bacteria removers, namely, antimicrobial preparations for inhibiting the growth of bacteria; biofilm removers, namely, antimicrobial preparations for inhibiting the growth of biofilms; biological preparations for the treatment of cancer and pseudomyxoma peritonei; chemical preparations containing enzymes for pharmaceutical purposes, namely, for the prevention and treatment of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD (chronic obstructive pulmonary disease), ARDS (acute respiratory distress syndrome), pneumonia, fungal infections and haemophilia; chemical preparations for pharmaceutical use, namely, for the prevention and treatment of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; compounds being pharmaceutical preparations for treating cancer; pharmaceutical compositions for the treatment and prevention of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; pharmaceutical preparations for the treatment and prevention of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the prevention and treatment of pseudomyxoma peritonei; pharmaceutical preparations for use in combination therapy for the treatment of cancer and pseudomyxoma peritonei; pharmaceutical preparations for treating glue ear, cystic fibrosis, sputum retention, chest infections, respiratory conditions, haemophilia, myocardial infarction, coronary artery disease, stroke, massive pulmonary embolism, acute limb ischemia, stent-related thrombosis or haemarthrosis; preparations of plants, namely, plant extracts for pharmaceutical useACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 3, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 3, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jan 3, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 3, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 18, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 2, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 2, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 13, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 28, 2021PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Sep 28, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 27, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 27, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 26, 2021ALIEASSIGNED TO LIE—
Sep 20, 2021ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jul 29, 2021GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jul 29, 2021GNSLLETTER OF SUSPENSION E-MAILED—
Jul 29, 2021CNSLSUSPENSION LETTER WRITTEN—
Jul 12, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 12, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 12, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 3, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 3, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 3, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 3, 2021DOCKASSIGNED TO EXAMINER—
Oct 27, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—

Frequently asked questions

Related guidance